consolidation chemotherapy and/or radiation treatment, patients were enrolled and commenced on panobinostat as a continuous daily oral dose starting at 10mg/m^2/day, with a three-week wash out period between therapies. Real-time acetylation status, measuring acetylated H4 on PMNC, was performed to determine the pharmacodynamics of panobinostat at different dosing levels. Patients were monitored for toxicity; dose reductions were in decrements of 2mg/m^2/day. RESULTS: A total of 13 patients with newly diagnosed ATRT/MRT and one patient with relapsed MRT have been enrolled. The average age at enrollment was 3.6 years (range 0.8-6.8 years). The mean treatment duration was 206 days (13-344 days). Currently, six patients (42.9%) remain on study with a mean study duration of 531 days (range 13-895 days). 6/14 patients (42.9%) were removed due to disease progression at a mean study duration of 245 days (44-560 days). 2/14 patients (14.3%) withdrew due to toxicity. 12/14 patients (85.7%) required dose reductions. The main toxicities were thrombocytopaenia and leukopaenia (Grade III-IV). Real-time pharmacodynamic assessment of panobinostat, at a dose as low as 6mg/m^2/day resulted in significant acetylation of histone H4 in PMNC. CONCLUSIONS: Treatment with low dose panobinostat is well tolerated in infants and children with MRT/ATRT, with significant acetylation of histone H4 in PMNC.

ATRT-18. ATYPICAL TERATOID/RHABDOID TUMOR IN CHILDREN: CASE REPORTS FROM INDONESIA

Diko Anugrah Ramadhan[1], Wanda Gautami[1], Ludi Dhyani Rahmartani[1], Ahmad Rafli[1], Kevin Gunawan[2], Mohamad Yanuar Amal[3], Eka Susanto[4], Handoko Handoko[5]; [1]Department of Child Health, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital,, Jakarta, DKI Jakarta, Indonesia. [2]Department of Neurosurgery, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia. [3]Department of Radiology, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia. [4]Department of Pathological Anatomy, Faculty of Medicine Universitas Indonesia, Jakarta, DKI Jakarta, Indonesia. [5]Department of Radiotherapy, Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo General Hospital, Jakarta, DKI Jakarta, Indonesia

Atypical teratoid/rhabdoid tumor (AT/RT) of the central nervous system is a sporadic and highly malignant tumor that usually affects very young children and is typically deadly despite very aggressive treatment. The optimal treatment for AT/RT remains unclear, including surgery, radiotherapy, and chemotherapy. Here we report cases of AT/RT in Indonesia. Case 1: A three-year-old girl came with worsening intermittent headaches with projectile vomiting, progressive and insidious right spastic hemiparesis, and slowly progressive weight loss three months before admission. She had septate multiloculated hydrocephalus. Head MRI demonstrates a solid lobulated mass with heterogeneous enhancement and MRS shows an aggressive metabolite pattern, arising from posterior fossa extending into the cerebellum and cerebellopontine angle, causing severe obstructive hydrocephalus. She underwent tumor resection with a midline suboccipital approach, then continued with craniospinal irradiation with dose of 36 Gy in 20 fractions then followed by 18 Gy in 10 fractions booster to posterior fossa, making the total dose to posterior fossa (the tumor) to be 54 Gy. Case 2: A twenty-month-old baby with a history of recurrent seizures, tremors, and less activity in the last two months. She had spasticity with hyperreflexia. She has been referred to our center for further evaluation and management after biopsy and VP shunt surgery at the previous hospital. Head CT scan demonstrates a large solid heterogeneous mass in the right hemisphere cerebral, causing midline shift and hydrocephalus. After the VP shunt was repaired, she underwent Head Start III chemotherapy protocol cycle 1. Both pathology examinations of the patients revealed a hypercellular tumor with prominent hyperchromatic nucleoli and loss of INI-1 staining on immunohistochemistry consistent with an ATRT diagnosis. Unfortunately, both patients died due to severe sepsis after treatment. Although AT/RT has become increasingly recognized, prognosis of ATRT is generally unfavorable, especially in developing countries.

ATRT-19. FUNCTIONAL GENOMICS REVEAL DISTINCT MODULATORS OF RESPONSE TO CDK4/6 INHIBITORS IN ATRTS

Daniel Merk[1,2], Sohpie Hirsch[1,2], Foteini Tsiami[1,2], Bianca Walter[1,2], Lara Haeusser[1,2], Sepideh Babaei[2], Jakob Admard[2], Nicolas Casadei[2], Cristiana Roggia[2], Michael Spohn[3], Jens Schittenhelm[2], Stephan Singer[2], Ulrich Schüller[3], Federica Piccioni[4], Nicole Persky[4], David Root[4], Manfred Claassen[2], Marcos Tatagiba[2], Ghazaleh Tabatabai[2]; [1]Hertie Institute for Clinical Brain Research, Tübingen, Germany. [2]University Hospital Tübingen, Tübingen, Germany. [3]Research Institute Children's Cancer Center, Hamburg, Germany. [4]Broad Institute of MIT and Harvard, Cambridge, USA

Brain tumors are the leading cause of cancer-related deaths in children, and atypical teratoid rhabdoid tumors (ATRTs) are among the most common aggressive brain tumors in infants. With no standard-of-care treatment so far, ATRTs continue to have relatively low survival estimates, illustrating the urgent need for more efficacious treatment options. We have previously used genome-wide CRISPR/Cas9 knockout screens in combination with small-molecule drug assays to identify targetable vulnerabilities in ATRTs. CDK4/6 inhibitors, among the most promising drugs in our study with direct translational potential, are capable of inhibiting tumor growth due to mutual exclusive dependency of ATRTs on either CDK4 or CDK6. We here used genome-wide loss-of-function and gain-of-function strategies to identify modulators of response to CDK4/6 inhibition in ATRTs. Of note, while some well-known resistance mechanisms such as loss of RB1 or FBXW7 are shared by ATRT cell lines, we have also identified modulators of response to CDK4/6 inhibition with opposing effects across ATRT cell lines. As such, loss of AMBRA1, a recently described master regulator of D type cyclins, can either oppose the effects of or synergize with CDK4/6 inhibitors based on the cellular background. We are currently using a proteomics approach to further delineate the mechanism driving this functional heterogeneity of AMBRA1 in ATRTs. Our study will therefore provide deeper insights into the response of ATRTs to CDK4/6 inhibitors, which represent one of the most promising class of targeted agents for the treatment of ATRTs.

ATRT-20. NOVEL PROGNOSTIC MOLECULAR SIGNATURES FOR IMPROVED RISK-CLASSIFICATION OF ATYPICAL TERATOID RHABDOID TUMOURS

Claire Keeling[1], Yura Grabovska[2], Patricia O'Hare[3,4], Stephen Crosier[1], Jessica C Pickles[4,5], Martina A Finetti[6,1], Amy R Fairchild[4,5], John Anderson[3,4], Darren Hargrave[3,4], Bernadette Brennan[7], Thomas S Jacques[4,5], Steven C Clifford[1], Simon Bailey[1,8], Daniel Williamson[1]; [1]Wolfson Childhood Cancer Research Centre, Newcastle University Centre for Cancer, Newcastle-upon-Tyne, United Kingdom. [2]The Institute of Cancer Research, London, United Kingdom. [3]UCL Great Ormond Street Institute of Child Health, London, United Kingdom. [4]Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom. [5]UCL, Great Ormond Street Institute of Child Health, London, United Kingdom. [6]Leeds University, Leeds, United Kingdom. [7]Royal Manchester Children's Hospital, Manchester, United Kingdom. [8]Great North Children's Hospital, Newcastle-upon-Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, United Kingdom

Malignant Rhabdoid Tumours (MRT) are aggressive paediatric malignancies seen in the central nervous system (Atypical Teratoid Rhabdoid Tumours (ATRT)), and kidney and other soft tissues (Extra-cranial Rhabdoid Tumours (ECRT)). With current therapies often proving ineffective and a lack of clear prognostic associations with consensus subgroups, we explored the possibility of using prognostic molecular signatures to further identify the biological characteristics of high risk ATRT patients. By employing a cross-validated feature selection method the methylation profiles of 121 MRT patients were analysed with clinical data to obtain meta-CpG signatures associated with prognosis for ATRT, ECRT and MRT. The relationship between these meta-CpG signatures and the consensus subgroups were further explored, along with the correlation of meta-CpGs with gene expression to establish biological significance. By selecting CpGs for their ability to predict survival this method obtained three novel prognostic methylation signatures which predict MRT outcome (ATRT-5, ECRT-14 and MRT-42). These signatures are independent of molecular subgroup and each signature was significantly associated with overall survival (OS) and event free survival (EFS) in their respective cohorts ($p<0.001$). Both ATRT-5 and MRT-42 maintained their significant association with OS in an independent ATRT cohort (n=64) and each meta-CPG signature is prognostically independent of other major clinical risk factors (e.g. receipt of radiotherapy and presence of metastases). Biologically, individuals with high-risk methylation signatures showed a gene expression profile suggestive of higher proliferative rates and tumours with low-risk scores in ATRT-5 and MRT-42 had an upregulated inflammatory response and increased immune infiltration. Combining these meta-CpGs with other significant clinical risk-factors produced high performing multivariate Cox-models enabling us to propose new stratification models for ATRT and MRT patients. These subgroup-independent prognostic signatures represent a distinct biology in ATRT and, if validated in prospective studies, could progress the use and efficacy of precision-based medicine in this therapeutically challenging disease.

ATRT-21. CONTRIBUTION OF GERMLINE MOSAIC ALTERATIONS OF SMARCB1 IN RHABDOID TUMOR PREDISPOSITION SYNDROME

Julien Masliah-Planchon[1], Laetitia Maillot[1], Noémie Rybak[1], Fatoumata Simaga[2], Abderaouf Hamza[1], Marion Gauthier Villars[2], Olivier Delattre[1], Franck Bourdeaut[3]; [1]Oncogenetic department, Institut Curie, Paris, France. [2]Clinical Oncogenetic, Institut Curie, Paris, France. [3]Pediatric departement,Institut Curie, Paris, France

Rhabdoid tumors are rare and aggressive tumors that usually arise in very young children. They are characterized by a bi-allelic inactivation of the *SMARCB1* gene. Although the majority of alterations of *SMARCB1* are acquired in tumors, a heterozygous germline alteration is seen in one third of patients and